Adaptive Biotechnologies (ADPT) Net Cash Flow Growth (3y) (2021 - 2026)
Adaptive Biotechnologies (ADPT) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 58.74% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -44.88% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 29.31% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 41.14% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 27.97% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -29.30% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -40.43% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -38.01% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -35.93% |
| 10 | Adaptive Biotechnologies | 4.23 Bn | 3.89 Bn | 51.39 Mn | 82.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.30% |
| Mar 31, 2026 | 16.46% |
| Dec 31, 2025 | 28.49% |
| Sep 30, 2025 | -56.22% |
| Jun 30, 2025 | 42.01% |
| Mar 31, 2025 | 28.17% |
| Dec 31, 2024 | -16.35% |
| Sep 30, 2024 | 29.40% |
| Jun 30, 2024 | -45.48% |
| Mar 31, 2024 | -50.20% |
| Dec 31, 2023 | 60.15% |
| Sep 30, 2023 | -29.19% |
| Jun 30, 2023 | -53.62% |
| Mar 31, 2023 | -66.16% |
| Dec 31, 2022 | -99.13% |
| Sep 30, 2022 | 70.33% |
| Jun 30, 2022 | 15.19% |
| Mar 31, 2022 | -34.39% |
| Dec 31, 2021 | -9.52% |
| Sep 30, 2021 | -111.87% |